Affy Says Q4 Revenues Up 13 Percent on 'Solid Increase' in Genotyping Sales

Driving the growth was increased adoption of its next-generation genotyping platform for genome-wide association studies, as well as "strong" sales of products for copy number studies, custom genotyping, and biomarker discovery and validation.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.